BYD Electronic Stock: Preliminary Results And Major Acquisition Draw Attention

AlexandrBognat/iStock via Getty Images Elevator Pitch I have a Buy investment rating for BYD Electronic (International) Company Limited (OTCPK:BYDIF) (OTCPK:BYDIY) [285:HK]. Previously, I touched on the risk relating to the company’s customer concentration, and BYDIF’s efforts to diversify its client mix in my June 1, 2020 article. In its 1H 2023 interim report, BYD Electronic…

Read More

Carlsberg: Solid 2023 Results, But Value Case Still Not Compelling (CABGY)

Bloomberg/Bloomberg via Getty Images Carlsberg (OTCPK:CABGY)(OTCPK:CABJF) stock has been on a tough run since I last covered the company in May. Shares of the Danish brewer have delivered a negative 18% total return in that time, significantly underperforming peers Heineken (OTCQX:HEINY)(OTCQX:HINKF) and Anheuser-Busch InBev (BUD) as well as global staples more generally. Data by YCharts…

Read More

UniCredit Q4 Earnings: 2024 Guidance Looks Bullish After Outstanding Results (UNCFF)

Emanuele Cremaschi/Getty Images News Italian bank UniCredit (OTCPK:UNCRY)(OTCPK:UNCFF) has continued on its upward march since I opened on the name with a Buy rating in October, with the ADSs delivering a circa 27% total return in that time amid significant outperformance against wider European financials. Data by YCharts Much of that outperformance came immediately following…

Read More

Hologic, Inc. (HOLX) Q1 2024 Results – Earnings Call Transcript

Hologic, Inc. (NASDAQ:HOLX) Q1 2024 Earnings Conference Call February 1, 2024 4:30 PM ET Company Participants Ryan Simon – Vice President, Investor Relations Steve MacMillan – Chairman, President and Chief Executive Officer Karleen Oberton – Chief Financial Officer Essex Mitchell – Chief Operating Officer Conference Call Participants Tejas Savant – Morgan Stanley Patrick Donnelly –…

Read More

Citigroup: I’m A Fan Of Q4 Results Despite The Bank Losing $1.8 Billion (NYSE:C)

_ultraforma_ Investment Thesis – Q4 FY23 Update Citigroup (NYSE:C) (Citi) remains one of my favorite big-bank stocks after what may seem like initially disappointing Q4 and full-year FY23 results. CEO Jane Fraser has accelerated the bank’s turnaround program with tangible qualitative progress being made in FY23. While earnings data supporting the thesis of increased ROE,…

Read More

Transcontinental: Q4 Results Support Dividend Yield And Upside (TSX:TCL.A:CA)

beingbonny/iStock via Getty Images Investment Thesis Transcontinental (TSX:TCL.A:CA) is a flexible packaging and printing company in North America. It reported its quarterly results and has managed to deliver decent performance despite the macroeconomic pressures. I believe the company can further grow in the future as it has highly focused on the commercialization of recyclable flexible…

Read More

SunOpta: Transformation Efforts Could Yield Results; Prospects Appear Baked In (STKL)

HandmadePictures/iStock via Getty Images SunOpta’s (NASDAQ:STKL) transformation initiatives appear to be a step in the right direction and could positively support growth and profitability. Prospects appear baked into the stock. Company Overview SunOpta is a Canadian manufacturer of plant-based beverages and creamers, protein shakes, teas, and broths, as well as fruit snacks, and smoothie bowls…

Read More

GMS Inc Stock: Mixed Q2 Results Keep Us On The Fence (NYSE:GMS)

FluxFactory GMS Inc (NYSE:GMS) recently reported its latest quarterly results, with revenue and EPS coming in above expectations. The company recognized as a leading manufacturer of wallboard, ceilings, and steal-framing installations has benefited from the resilient construction activity despite the volatile macro backdrop over the past year. Indeed, the stock is up more than 40%…

Read More

X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying (NASDAQ:XFOR)

Md Babul Hosen Brief summary of prior coverage X4 Pharmaceuticals (NASDAQ:XFOR) is developing mavorixafor for WHIM (a rare inherited form of chronic neutropenia), as well as for a broader chronic neutropenia patient population. Mavorixafor’s mechanism of action is ideal for WHIM and results from clinical trials are very convincing for an eventual approval in WHIM….

Read More

Meridian Corporation Offers Attractive Prospects Despite Volatile Results (NASDAQ:MRBK)

VioletaStoimenova Rarely will you come across the ‘perfect’ investment opportunity. Most investments that you make in your life will, instead, involve trade-offs. As an example, smaller companies tend to be riskier than larger ones. But at the same time, they can also be overlooked and offer additional upside that you wouldn’t expect from larger prospects….

Read More

Travel + Leisure: Despite Mixed Results, Significant Recurrent Revenue And Growth

Igor Vershinsky/iStock via Getty Images Travel + Leisure Co. (NYSE:TNL) recently delivered mixed quarterly results, but the company continues to deliver quarterly net sales growth and adjusted EBITDA growth. In my view, the significant amount of recurrent revenue, recent dividend growth, and the potential of the network effects established with brands and hotels will most…

Read More

Decoding NetApp’s Fiscal Q2 Results: Risks And Opportunities (NASDAQ:NTAP)

pixdeluxe NetApp (NASDAQ:NTAP), a notable player in the technology sector, has consistently demonstrated resilience and adaptability amidst a challenging landscape. Our in-depth analysis of the company’s Q2 2024 earnings, recent earnings call, and valuation metrics paints a complex yet promising picture. NetApp’s robust financial health and operational efficiency are commendable despite notable macroeconomic pressures and…

Read More

Ashland: Poor Results And High Valuation (NYSE:ASH)

SweetBunFactory Ashland (NYSE:ASH) offers specialty ingredients and additives worldwide. ASH recently announced Q4 FY23 and FY23 results. They struggled in FY23 due to a destocking issue, which is expected to affect them in FY24. So, the outlook for FY24 isn’t that positive, and its valuation seems high. So, I think ASH might be unable to…

Read More

Ulta Beauty: Strong Q3 Results Prove Its Resilience (NASDAQ:ULTA)

jetcityimage Investment Thesis Ulta Beauty (NASDAQ:ULTA) stands out as a company with a remarkable historical performance, consistently showcasing robust financial strength year after year. This is not what one would expect from a retail business, which often entails low competitive advantages, narrow margins and revenues closely linked to discretionary consumption. Acknowledging Ulta’s significant position in…

Read More

MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis (MOR)

tonaquatic Thesis overview MorphoSys AG (NASDAQ:MOR) recently announced positive topline results from its phase 3 trial of pelabresib in myelofibrosis (MF). The study easily met the primary endpoint. However, despite the strong positive trend, statistical significance was not achieved at key secondary endpoints assessing symptomatic improvement. Nevertheless, in a pre-specified subgroup analysis in intermediate-risk patients…

Read More

Eaton Corporation: Navigating A Complex Business Environment With Robust Results (NYSE:ETN)

tianyu wu In this comprehensive analysis, we explore the performance and strategic direction of Eaton Corporation (NYSE:ETN), one of the leading names in power management. Beyond the surface of quarterly earnings, we delve into the company’s business strategy, its response to market trends, and its management of various challenges. Eaton’s ability to deliver impressive financial…

Read More

Futu Holdings Stock: Mixed Results (NASDAQ:FUTU)

Asia-Pacific Images Studio/E+ via Getty Images Elevator Pitch My rating for Futu Holdings Limited (NASDAQ:FUTU) shares is a Hold. I previously touched on the regulatory developments associated with FUTU’s business operations in my prior March 9, 2023 update. In this latest article, my focus is on the review of Futu Holdings’ financial results for the…

Read More

Funko Reports Slightly Better Q3 Results, Stock Price Likely To Drop More (NASDAQ:FNKO)

Joe Scarnici Funko (NASDAQ:FNKO) has been right-sizing its business operations, inventory stock, and product lines in an attempt to show better profits and net income. The company recently reported better financial performance compared to the last three quarters. It shows improvement but it will take more time for there to be significant improvement. The current…

Read More